From physician key-person risk to CPOM compliance failures, learn what experienced buyers get wrong and how to protect your investment.
Find Vetted Dermatology Practice DealsAcquiring a dermatology practice offers strong returns, but buyers routinely overpay, overlook physician dependency risks, or mishandle corporate practice of medicine laws. These six mistakes can destroy deal value before the ink dries.
Market Size
Approximately $20 billion in the U.S. dermatology services market, with the aesthetic dermatology segment projected to exceed $5 billion
Growth Trend
Growing
Recession Resistant
Yes
Market Structure
Highly fragmented
Paying a 6x multiple on a practice where one physician drives 80% of revenue is a critical error. If that dermatologist exits post-close, you've acquired an empty building with a patient list.
How to avoid: Require at least two licensed providers generating revenue. Negotiate physician equity rollover and earnouts tied to continued production to align incentives post-acquisition.
Assuming physician non-competes are enforceable without state-specific legal review is dangerous. Several states restrict or void non-competes for licensed physicians, leaving you exposed.
How to avoid: Engage a healthcare M&A attorney to review all non-competes under the applicable state's laws before signing a LOI. Restructure agreements if necessary.
Structuring a direct ownership deal without accounting for CPOM regulations can result in unlicensed practice of medicine violations, voided contracts, and regulatory penalties.
How to avoid: Use an MSO structure that separates clinical from business operations. Confirm your deal structure complies with the specific state's CPOM statute before closing.
Cosmetic revenue from Botox, fillers, and laser treatments is often physician-specific. Buyers who capitalize cosmetic income without confirming patient loyalty to the practice—not the doctor—overpay significantly.
How to avoid: Request appointment-level data segmented by provider. Apply a conservative discount to cosmetic revenue in your valuation model if tied to a departing physician.
Acquiring a practice with claims-made malpractice policies without securing tail coverage leaves you financially exposed to claims arising from pre-close incidents.
How to avoid: Require the seller to purchase tail coverage as a closing condition. Clarify occurrence vs. claims-made policy status early in due diligence.
Legacy EMR platforms and fragmented revenue cycle management systems are common in independent dermatology practices. Buyers routinely underestimate the time and cost of integration.
How to avoid: Audit the current EMR system and billing workflow during due diligence. Budget for migration costs and plan for temporary revenue cycle disruption during transition.
Buyers submit SBA loan applications before independently verifying the Dermatology Practice's normalized EBITDA. When diligence reveals add-backs that don't hold, the deal's debt service coverage collapses and the loan fails underwriting.
How to avoid: Build your EBITDA model with conservative add-back assumptions before engaging an SBA lender. At current rates, a $1M SBA 7(a) loan costs approximately $13,000/month — the Dermatology Practice needs $195,000+ in post-salary EBITDA to clear 1.25x DSCR.
Buyers close on a Dermatology Practice assuming operations transfer smoothly, then discover undocumented processes, informal vendor relationships, and staff who rely on institutional knowledge the seller carries in their head.
How to avoid: Require a 60-day operational documentation period before closing. Walk through every key process with the seller present, document staff responsibilities, vendor contacts, and customer communication protocols. Build a 90-day integration plan before the wire hits.
What experienced buyers verify before committing to a Dermatology Practice acquisition.
The specific concerns and miscalculations buyers face in this industry.
Common miscalculations sellers make that reduce their final price or derail a deal.
Independent dermatology practices typically trade at 4x–7x EBITDA. Practices with multiple providers, strong cosmetic revenue, and diversified payer mix command the higher end of that range.
Yes. Dermatology practices are SBA 7(a) eligible. Most deals combine an SBA loan with a seller note covering 10–15% of the purchase price and a 12–24 month seller transition period.
An MSO allows a non-physician entity to manage business operations while a physician-owned PC retains clinical control, satisfying corporate practice of medicine laws in restrictive states.
Structure physician compensation with equity rollover, earnouts tied to EBITDA performance, and enforceable non-competes. Multi-year employment agreements with meaningful retention bonuses also reduce departure risk.
More Dermatology Practice Guides
DealFlow OS helps you find and evaluate acquisitions with seller signals and due diligence tools. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers